TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy.
Julia EckardtChristopher SchroederPeter MartusSorin Armeanu-EbingerOlga KelemenAxel GschwindIrina BonzheimThomas EigentlerTeresa AmaralStephan OssowskiOlaf RießLukas FlatzClaus GarbeAndrea ForschnerPublished in: Journal of cancer research and clinical oncology (2022)
BRAF mutation status and TMB were independent predictive factors for RFS. Patients with BRAF V600E/K mutation and TMB high had the best outcome. A classification based on BRAF mutation status and TMB is proposed to predict RFS in melanoma patients with adjuvant anti-PD-1 therapy.